Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas a randomized controlled trial

Bruce R. Carr, Elizabeth A. Stewart, David F. Archer, Ayman Al-Hendy, Linda Bradley, Nelson B. Watts, Michael Peter Diamond, Jingjing Gao, Charlotte D. Owens, Kristof Chwalisz, W. Rachel Duan, Ahmed M. Soliman, Matthew B. Dufek, James A. Simon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-controlled, parallel-group study evaluated efficacy and safety of elagolix in cohorts 1 (300 mg twice daily) and 2 (600 mg daily) with four arms per cohort: placebo, elagolix alone, elagolix with 0.5 mg estradiol/0.1 norethindrone acetate, and elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate. A sample size of 65 per group was planned to compare elagolix with add-back to placebo on the primary end point: the percentage of women who had less than 80 mL menstrual blood loss and 50% or greater reduction in menstrual blood loss from baseline to the last 28 days of treatment. Safety assessments included changes in bone mineral density. RESULTS: From April 8, 2013, to December 8, 2015, 571 women were enrolled, 567 were randomized and treated (cohort 15259; cohort 25308), and 80% and 75% completed treatment, respectively. Participants had a mean6SD age of 4365 years (cohort 2, 4265 years), and 70% were black (cohort 2, 74%). Primary end point responder rates in cohort 1 (cohort 2) were 92% (90%) for elagolix alone, 85% (73%) for elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate, 79% (82%) for elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate, and 27% (32%) for placebo (all P,.001 vs placebo). Elagolix groups had significant decreases compared with placebo in lumbar spine bone mineral density, which was attenuated by adding 1.0 mg estradiol/0.5 mg norethindrone acetate. CONCLUSION: Elagolix with and without add-back significantly reduced menstrual blood loss in women with uterine leiomyomas. Add-back therapy reduced hypoestrogenic effects on bone mineral density. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01817530; EU Clinical Trial Register, 2013-000082-37.

Original languageEnglish (US)
Pages (from-to)1252-1264
Number of pages13
JournalObstetrics and Gynecology
Volume132
Issue number5
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Leiomyoma
Randomized Controlled Trials
Hemorrhage
Placebos
Estradiol
Therapeutics
Bone Density
elagolix
Clinical Trials
LHRH Receptors
Hormone Antagonists
Safety
Sample Size
Spine
norethindrone acetate

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas a randomized controlled trial. / Carr, Bruce R.; Stewart, Elizabeth A.; Archer, David F.; Al-Hendy, Ayman; Bradley, Linda; Watts, Nelson B.; Diamond, Michael Peter; Gao, Jingjing; Owens, Charlotte D.; Chwalisz, Kristof; Rachel Duan, W.; Soliman, Ahmed M.; Dufek, Matthew B.; Simon, James A.

In: Obstetrics and Gynecology, Vol. 132, No. 5, 01.01.2018, p. 1252-1264.

Research output: Contribution to journalArticle

Carr, BR, Stewart, EA, Archer, DF, Al-Hendy, A, Bradley, L, Watts, NB, Diamond, MP, Gao, J, Owens, CD, Chwalisz, K, Rachel Duan, W, Soliman, AM, Dufek, MB & Simon, JA 2018, 'Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas a randomized controlled trial', Obstetrics and Gynecology, vol. 132, no. 5, pp. 1252-1264. https://doi.org/10.1097/AOG.0000000000002933
Carr, Bruce R. ; Stewart, Elizabeth A. ; Archer, David F. ; Al-Hendy, Ayman ; Bradley, Linda ; Watts, Nelson B. ; Diamond, Michael Peter ; Gao, Jingjing ; Owens, Charlotte D. ; Chwalisz, Kristof ; Rachel Duan, W. ; Soliman, Ahmed M. ; Dufek, Matthew B. ; Simon, James A. / Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas a randomized controlled trial. In: Obstetrics and Gynecology. 2018 ; Vol. 132, No. 5. pp. 1252-1264.
@article{19c97b701eae4183b5e4361d445f78aa,
title = "Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas a randomized controlled trial",
abstract = "OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-controlled, parallel-group study evaluated efficacy and safety of elagolix in cohorts 1 (300 mg twice daily) and 2 (600 mg daily) with four arms per cohort: placebo, elagolix alone, elagolix with 0.5 mg estradiol/0.1 norethindrone acetate, and elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate. A sample size of 65 per group was planned to compare elagolix with add-back to placebo on the primary end point: the percentage of women who had less than 80 mL menstrual blood loss and 50{\%} or greater reduction in menstrual blood loss from baseline to the last 28 days of treatment. Safety assessments included changes in bone mineral density. RESULTS: From April 8, 2013, to December 8, 2015, 571 women were enrolled, 567 were randomized and treated (cohort 15259; cohort 25308), and 80{\%} and 75{\%} completed treatment, respectively. Participants had a mean6SD age of 4365 years (cohort 2, 4265 years), and 70{\%} were black (cohort 2, 74{\%}). Primary end point responder rates in cohort 1 (cohort 2) were 92{\%} (90{\%}) for elagolix alone, 85{\%} (73{\%}) for elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate, 79{\%} (82{\%}) for elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate, and 27{\%} (32{\%}) for placebo (all P,.001 vs placebo). Elagolix groups had significant decreases compared with placebo in lumbar spine bone mineral density, which was attenuated by adding 1.0 mg estradiol/0.5 mg norethindrone acetate. CONCLUSION: Elagolix with and without add-back significantly reduced menstrual blood loss in women with uterine leiomyomas. Add-back therapy reduced hypoestrogenic effects on bone mineral density. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01817530; EU Clinical Trial Register, 2013-000082-37.",
author = "Carr, {Bruce R.} and Stewart, {Elizabeth A.} and Archer, {David F.} and Ayman Al-Hendy and Linda Bradley and Watts, {Nelson B.} and Diamond, {Michael Peter} and Jingjing Gao and Owens, {Charlotte D.} and Kristof Chwalisz and {Rachel Duan}, W. and Soliman, {Ahmed M.} and Dufek, {Matthew B.} and Simon, {James A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/AOG.0000000000002933",
language = "English (US)",
volume = "132",
pages = "1252--1264",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas a randomized controlled trial

AU - Carr, Bruce R.

AU - Stewart, Elizabeth A.

AU - Archer, David F.

AU - Al-Hendy, Ayman

AU - Bradley, Linda

AU - Watts, Nelson B.

AU - Diamond, Michael Peter

AU - Gao, Jingjing

AU - Owens, Charlotte D.

AU - Chwalisz, Kristof

AU - Rachel Duan, W.

AU - Soliman, Ahmed M.

AU - Dufek, Matthew B.

AU - Simon, James A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-controlled, parallel-group study evaluated efficacy and safety of elagolix in cohorts 1 (300 mg twice daily) and 2 (600 mg daily) with four arms per cohort: placebo, elagolix alone, elagolix with 0.5 mg estradiol/0.1 norethindrone acetate, and elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate. A sample size of 65 per group was planned to compare elagolix with add-back to placebo on the primary end point: the percentage of women who had less than 80 mL menstrual blood loss and 50% or greater reduction in menstrual blood loss from baseline to the last 28 days of treatment. Safety assessments included changes in bone mineral density. RESULTS: From April 8, 2013, to December 8, 2015, 571 women were enrolled, 567 were randomized and treated (cohort 15259; cohort 25308), and 80% and 75% completed treatment, respectively. Participants had a mean6SD age of 4365 years (cohort 2, 4265 years), and 70% were black (cohort 2, 74%). Primary end point responder rates in cohort 1 (cohort 2) were 92% (90%) for elagolix alone, 85% (73%) for elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate, 79% (82%) for elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate, and 27% (32%) for placebo (all P,.001 vs placebo). Elagolix groups had significant decreases compared with placebo in lumbar spine bone mineral density, which was attenuated by adding 1.0 mg estradiol/0.5 mg norethindrone acetate. CONCLUSION: Elagolix with and without add-back significantly reduced menstrual blood loss in women with uterine leiomyomas. Add-back therapy reduced hypoestrogenic effects on bone mineral density. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01817530; EU Clinical Trial Register, 2013-000082-37.

AB - OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-controlled, parallel-group study evaluated efficacy and safety of elagolix in cohorts 1 (300 mg twice daily) and 2 (600 mg daily) with four arms per cohort: placebo, elagolix alone, elagolix with 0.5 mg estradiol/0.1 norethindrone acetate, and elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate. A sample size of 65 per group was planned to compare elagolix with add-back to placebo on the primary end point: the percentage of women who had less than 80 mL menstrual blood loss and 50% or greater reduction in menstrual blood loss from baseline to the last 28 days of treatment. Safety assessments included changes in bone mineral density. RESULTS: From April 8, 2013, to December 8, 2015, 571 women were enrolled, 567 were randomized and treated (cohort 15259; cohort 25308), and 80% and 75% completed treatment, respectively. Participants had a mean6SD age of 4365 years (cohort 2, 4265 years), and 70% were black (cohort 2, 74%). Primary end point responder rates in cohort 1 (cohort 2) were 92% (90%) for elagolix alone, 85% (73%) for elagolix with 0.5 mg estradiol/0.1 mg norethindrone acetate, 79% (82%) for elagolix with 1.0 mg estradiol/0.5 mg norethindrone acetate, and 27% (32%) for placebo (all P,.001 vs placebo). Elagolix groups had significant decreases compared with placebo in lumbar spine bone mineral density, which was attenuated by adding 1.0 mg estradiol/0.5 mg norethindrone acetate. CONCLUSION: Elagolix with and without add-back significantly reduced menstrual blood loss in women with uterine leiomyomas. Add-back therapy reduced hypoestrogenic effects on bone mineral density. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01817530; EU Clinical Trial Register, 2013-000082-37.

UR - http://www.scopus.com/inward/record.url?scp=85059829503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059829503&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000002933

DO - 10.1097/AOG.0000000000002933

M3 - Article

C2 - 30303923

AN - SCOPUS:85059829503

VL - 132

SP - 1252

EP - 1264

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5

ER -